Literature DB >> 16179567

Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine.

Daniela Poli1, Emilia Antonucci, Emanuele Cecchi, Rossella Marcucci, Agatina Alessandrello Liotta, Anna Paola Cellai, Meri Lenti, Gian Franco Gensini, Rosanna Abbate, Domenico Prisco.   

Abstract

BACKGROUND AND
PURPOSE: In patients with atrial fibrillation (AF), oral anticoagulant therapy (OAT) is effective in reducing stroke and embolism. However, despite OAT, ischemic events do occur in some patients. Studies specifically addressing the identification of risk factors for ischemic events during well-conducted OAT are not available. In this study, we prospectively investigated the role of classic risk factors and homocysteine levels in the occurrence of ischemic complications in 364 AF patients on OAT.
METHODS: The quality of anticoagulation levels and the occurrence of bleeding and thrombotic events were recorded.
RESULTS: During follow-up (859 patient years) 21 patients had ischemic complications (rate 2.4 x 100 patient-years). Homocysteine plasma levels were higher in these patients than in patients without ischemic complications during OAT (P<0.01), whereas no difference was observed in relation to the quality of OAT. The presence of a history of previous ischemic events, hypertension, and homocysteine plasma levels over the 90th percentile were all associated with an increased risk of ischemic events during OAT (odds ratio [OR]=7, 4.5, and 4.7, respectively). The coexistence of these risk factors markedly increased the risk (OR=13.1; 95% CI, 3.7 to 45.7; P=0.001).
CONCLUSIONS: In conclusion, our results indicate that AF patients with multiple risk factors may not be sufficiently protected by OAT, even when this is well conducted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179567     DOI: 10.1161/01.STR.0000183620.06179.7b

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  19 in total

Review 1.  Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels.

Authors:  Adedotun A Ogunsua; Amir Y Shaikh; Mohamed Ahmed; David D McManus
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Oct-Dec

2.  Laboratory characteristics of ischemic stroke patients with atrial fibrillation on or off therapeutic warfarin.

Authors:  Raghav V Aachi; Lee A Birnbaum; Christopher H Topel; Ali Seifi; Shaheryar Hafeez; Réza Behrouz
Journal:  Clin Cardiol       Date:  2017-12-18       Impact factor: 2.882

3.  Atrial fibrillation and stroke prevention: is warfarin still an option? Yes: Debate at the Controversies in Neurology Congress, Beijing, October 2011.

Authors:  J David Spence
Journal:  J Neural Transm (Vienna)       Date:  2012-12-12       Impact factor: 3.575

4.  Left Atrial Thrombus Despite Anticoagulation: The Importance Of Homocysteine.

Authors:  J David Spence
Journal:  J Atr Fibrillation       Date:  2013-08-31

Review 5.  Secondary stroke prevention.

Authors:  J David Spence
Journal:  Nat Rev Neurol       Date:  2010-08-10       Impact factor: 42.937

Review 6.  Antihypertensive treatment can prevent stroke and cognitive decline.

Authors:  Peter Sörös; Shawn Whitehead; J David Spence; Vladimir Hachinski
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

7.  The risk stratification in atrial fibrillation.

Authors:  Domenico Prisco; Caterina Cenci; Elena Silvestri; Giacomo Emmi; Tommaso Barnini; Carlo Tamburini
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

8.  Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine.

Authors:  J David Spence; Bradley L Urquhart; Heejung Bang
Journal:  Nephrol Dial Transplant       Date:  2015-11-14       Impact factor: 5.992

9.  Plasma Total Homocysteine Level Is Related to Unfavorable Outcomes in Ischemic Stroke With Atrial Fibrillation.

Authors:  Ki-Woong Nam; Chi Kyung Kim; Sungwook Yu; Kyungmi Oh; Jong-Won Chung; Oh Young Bang; Gyeong-Moon Kim; Jin-Man Jung; Tae-Jin Song; Yong-Jae Kim; Bum Joon Kim; Sung Hyuk Heo; Kwang-Yeol Park; Jeong-Min Kim; Jong-Ho Park; Jay Chol Choi; Man-Seok Park; Joon-Tae Kim; Kang-Ho Choi; Yang Ha Hwang; Woo-Keun Seo
Journal:  J Am Heart Assoc       Date:  2022-04-26       Impact factor: 6.106

Review 10.  Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies.

Authors:  Neil S Roskell; Miny Samuel; Herbert Noack; Brigitta U Monz
Journal:  Europace       Date:  2013-02-13       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.